共 50 条
Combining host modulation and topical antimicrobial therapy in the management of moderate to severe periodontitis: A randomized multicenter trial
被引:4
|作者:
Novak, M. John
[1
]
Dawson, Dolphus R., III
[1
]
Maonusson, Ingvar
[2
]
Karpinia, Katherine
[2
]
Polson, Alan
[3
]
Polson, Anne
[3
]
Ryan, Maria E.
[4
]
Ciancio, Sebastian
[5
]
Drisko, Co-Nnie H.
Kinane, Denis
[6
]
Powala, Christopher
[7
]
Bradshaw, Mark
机构:
[1] Univ Kentucky, Ctr Oral Hlth Res, Lexington, KY 40536 USA
[2] Univ Florida, Dept Periodont, Gainesville, FL USA
[3] Univ Penn, Dept Periodont, Philadelphia, PA 19104 USA
[4] SUNY Stony Brook, Dept Oral Biol & Pathol, Stony Brook, NY 11794 USA
[5] SUNY Buffalo, Dept Periodont, Buffalo, NY 14260 USA
[6] Univ Louisville, Louisville, KY 40292 USA
[7] CollaGenex Pharmaceut, Newtown, PA USA
关键词:
clinical trial;
periodontitis;
root planing;
therapy;
D O I:
10.1902/jop.2008.070237
中图分类号:
R78 [口腔科学];
学科分类号:
1003 ;
摘要:
Background: Previous studies showed that host modulation therapy (HMT) or topical antimicrobial therapy (TAT) provided significant adjunctive benefits to scaling and root planing (SRP) in the treatment of chronic periodontitis (CP). The purpose of this study was to evaluate a combination therapy involving SRP, HMT, and TAT in the treatment of moderate to severe CP. Methods: A 6-month, randomized, multicenter, placebo-controlled, examiner-masked study was undertaken to evaluate the clinical usefulness of a combination treatment of systemically delivered doxycycline hyclate (HMT; 20 mg, twice a day) plus locally delivered doxycycline hyclate gel (TAT; 10%, in pockets 5 mm) in combination with SRP versus SRP plus placebo. Clinical outcomes included mean changes in probing depth (PD), clinical attachment level (CAL), bleeding on probing (BOP), and gingival index (GI) at baseline and at 3 and 6 months. Results: In 171 subjects, combination therapy provided significantly greater clinical benefits than control therapy for all clinical measures at 3 and 6 months. In moderate CP (PD of 4 to 6 mm), combination therapy provided significant benefits over control for PD (3 and 6 months: P <0.01), CAL (3 months: P <0.01; 6 months: P <0.03), BOP (3 months: P <0.02; 6 months: P <0.05), and GI (3 months: P <0.01; 6 months: P<0.03). In severe CP (PD >= 7 mm), combination therapy provided significant benefits over control for PD (3 and 6 months: P<0.01), CAL (3 months: P<0.01; 6 months: P<0.02), BOP (3 months: P<0.01; 6 months: P>0.05), and GI (3 months: P<0.01; 6 months: P<0.01). Conclusion: Combination therapy, including SRP, HMT, and TAT, provided significantly greater clinical benefits than SRP alone in the treatment of moderate to severe CP.
引用
收藏
页码:33 / 41
页数:9
相关论文